Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has received an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $3.1667.

INO has been the subject of several recent research reports. Piper Sandler reissued an “overweight” rating and set a $4.00 price target on shares of Inovio Pharmaceuticals in a research report on Monday, August 3rd. Wall Street Zen upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Jefferies Financial Group upgraded Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and lifted their price objective for the stock from $1.80 to $3.00 in a research report on Thursday, August 13th. Weiss Ratings downgraded shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. Finally, HC Wainwright restated a “neutral” rating on shares of Inovio Pharmaceuticals in a report on Thursday, August 13th.

Inovio Pharmaceuticals Stock Performance

Shares of INO opened at $1.25 on Monday. The stock has a market cap of $129.25 million, a P/E ratio of -1.37 and a beta of 1.63. The company has a 50-day moving average of $1.10 and a two-hundred day moving average of $1.25. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.72.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. As a group, analysts forecast that Inovio Pharmaceuticals will post -0.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the company. Headlands Technologies LLC purchased a new stake in Inovio Pharmaceuticals in the 2nd quarter worth approximately $33,000. Focus Partners Wealth purchased a new position in shares of Inovio Pharmaceuticals during the 3rd quarter worth $33,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Inovio Pharmaceuticals by 39.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 5,894 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Inovio Pharmaceuticals by 752.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 18,160 shares during the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in shares of Inovio Pharmaceuticals in the second quarter valued at $37,000. Hedge funds and other institutional investors own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.